Mepolizumab intravenous (IV) vs placeboHealth‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 369 participantsHigh
Reslizumab intravenous (IV) vs placeboHealth‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1164 participantsHigh
Reslizumab subcutaneous (SC) vs placeboHealth‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 464 participantsHigh
Benralizumab subcutaneous (SC) vs placeboHealth‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1541 participantsHigh